Candel Therapeutics (CADL) Non Operating Income (2020 - 2025)

Candel Therapeutics has disclosed Non Operating Income across 6 years of filings, most recently posting -$23.7 million for Q4 2025.

• Non Operating Income for Q4 2025 came in at -$23.7 million, down 300.19% year-over-year; the trailing twelve-month figure through Dec 2025 was $89000.0 (up 100.41% YoY), and the FY2025 annual result was $89000.0, up 100.41% from the prior year.
• Non Operating Income came in at -$23.7 million for Q4 2025 at Candel Therapeutics, down from $1.9 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $15.5 million in Q1 2025 to a low of -$23.7 million in Q4 2025.
• The 5-year median for Non Operating Income is $155000.0 (2021), against an average of -$414850.0.
• Across the five-year window, Non Operating Income soared 6521.28% in 2021 and tumbled 38945.71% in 2024, its largest moves.
• Candel Therapeutics' Non Operating Income stood at $9.3 million in 2021, then slumped by 67.67% to $3.0 million in 2022, then tumbled by 125.75% to -$777000.0 in 2023, then sank by 663.45% to -$5.9 million in 2024, then slumped by 300.19% to -$23.7 million in 2025.
• The last three Non Operating Income figures came in at -$23.7 million (Q4 2025), $1.9 million (Q3 2025), and $6.4 million (Q2 2025), per Business Quant data.